

## Arcadium Lithium Form S-4 Registration Statement Declared Effective

Allkem Limited (ASX and TSX: AKE, “**Allkem**”) confirms that Arcadium Lithium plc’s (“**Arcadium Lithium**”) registration statement on Form S-4, which contains a proxy statement / prospectus (“**Form S-4**”), filed with the U.S. Securities and Exchange Commission (“**SEC**”) has now become effective.

The Form S-4 is issued by Arcadium Lithium in connection with the proposed merger of equals (“**Transaction**”) between Allkem and Livent Corporation (“**Livent**”), and serves as both a proxy statement of Livent (to solicit proxies for the meeting of Livent stockholders that will be held on Tuesday, 19 December 2023) and as a prospectus (relating to the Arcadium Lithium shares to be issued to Livent stockholders under the Transaction).

The Form S-4 becoming effective satisfies another condition to implementation of the Transaction.

### *No reliance on Form S-4 by Allkem Shareholders*

The Form S-4 should not be relied on by Allkem shareholders in deciding whether to vote for or against the Scheme (or by any other person in deciding to make an investment decision with respect to Allkem securities). Allkem refers to the statements concerning non-reliance on the Form S-4 in its announcements dated 24 July 2023 and 28 September 2023 (in relation to filings of the Preliminary Form S-4), which apply equally – save for the cautionary statements related to the preliminary nature of those initial filings – to the Form S-4.

Allkem shareholders should continue to refer to the Scheme Booklet that was released to ASX on 9 November 2023 and subsequently dispatched to Allkem shareholders. The Scheme Booklet is available on ASX’s website (at: [www.asx.com.au](http://www.asx.com.au)) and at Allkem’s website (at: [www.allkem.co](http://www.allkem.co)) as well as on Allkem’s SEDAR+ directory (at: [www.sedarplus.ca](http://www.sedarplus.ca)).

For completeness only, a copy of the Form S-4 is accessible on the SEC’s EDGAR platform at: [www.sec.gov](http://www.sec.gov).

ENDS

This release was authorised by the Board of Directors of Allkem

 <b>Allkem Limited</b> ABN 31 112 589 910 Level 35, 71 Eagle St Brisbane, QLD 4000	<b>Investor Relations &amp; Media Enquiries</b>	<b>Connect</b>
	Andrew Barber <b>M:</b> +61 418 783 701 <b>E:</b> <a href="mailto:Andrew.Barber@allkem.co">Andrew.Barber@allkem.co</a> Phoebe Lee <b>P:</b> +61 7 3064 3600 <b>E:</b> <a href="mailto:Phoebe.Lee@allkem.co">Phoebe.Lee@allkem.co</a>	<a href="mailto:info@allkem.co">info@allkem.co</a> +61 7 3064 3600 <a href="http://www.allkem.co">www.allkem.co</a> in f t y

## IMPORTANT NOTICES

### **Not for release or distribution in the United States**

This announcement has been prepared for publication in Australia and Canada and may not be released to U.S. wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction, and neither this announcement or anything attached to this announcement shall form the basis of any contract or commitment. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions registered under the U.S. Securities Act of 1933 or exempt from, or not subject to, the registration of the U.S. Securities Act of 1933 and applicable U.S. state securities laws.